Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130 EUR | -1.03% | -0.08% | +9.42% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 34.73 and 22.59 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.42% | 14.28B | - | ||
+9.42% | 114B | B+ | ||
+11.84% | 104B | B+ | ||
-14.15% | 22.41B | B+ | ||
-1.05% | 22.28B | B | ||
-5.29% | 19.07B | A- | ||
-38.29% | 18B | A- | ||
-4.16% | 17.89B | B | ||
+36.24% | 12.55B | C+ | ||
-24.95% | 8.45B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock
- Ratings Neurocrine Biosciences, Inc.